Video

Dr. Soliman on the Rationale for Using Immunotherapy in TNBC

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the rationale for using immunotherapy in triple-negative breast cancer (TNBC).

More aggressive subtypes of breast cancer can elicit tumor lymphocyte infiltration, says Soliman, making TNBC an ideal cancer for immunotherapy.

In contrast to immunologically “cold” tumors, inflamed tumors are good targets for checkpoint inhibitors, such as atezolizumab (Tecentriq) or pembrolizumab (Keytruda), Soliman explains.

As such, TNBC has biologic rationale for immunotherapy. Moreover, clinical research has shown that TNBC appears to be more amenable to immunotherapy compared with hormone receptor–positive breast cancer.

Immunotherapy should continue to be evaluated in the TNBC paradigm, concludes Soliman.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity